Preliminary Analysis of PSMA-Targeted 18F-DCFPyL PET/MRI for Assessment of Response to Neo-Adjuvant Chemohormonal Therapy in Men with High-Risk Primary Prostate Cancer

Conclusions: Preliminary analysis demonstrates DCFPyL PSMA PET/MR can assess response to neoadjuvant chemohormal therapy in men with high-risk primary PCa. PET SUVmax was correlated with PSA and early PSA recurrence. Further analyses to explore correlation of PSMA PET with histopathological response, clinical outcomes and tumor microenvironment studies are ongoing.

Source: Journal of Nuclear Medicine - May 14, 2020 Category: Nuclear Medicine Authors: Cho, S., Wells, S., Kyriakopoulos, C., Johnson, B., Roldan, A., Huang, W., Beebe, D., Emamekhoo, H., Jarrard, D., Lang, J. Tags: GU - PSMA PET (Poster Session) Source Type: research